Weight change over two years in people prescribed olanzapine,quetiapine and risperidone in UK primary care: Cohort study in THIN,a UK primary care database

Abstract

Background:

Follow-up studies of weight gain related to antipsychotic treatment beyond a year are limited in number. We compared weight change in the three most commonly prescribed antipsychotics in a representative UK General Practice database.

Method:

We conducted a cohort study in United Kingdom primary care records of people newly prescribed olanzapine, quetiapine or risperidone. The primary outcome was weight in each six month period for two years after treatment initiation. Weight changes were compared using linear regression, adjusted for age, baseline weight and diagnosis.

Results:

N = 6338 people received olanzapine, 12,984 quetiapine and 6556 risperidone. Baseline weight was lowest for men treated with olanzapine (80.8 kg versus 83.5 kg quetiapine, 82.0 kg risperidone) and women treated with olanzapine (67.7 kg versus 71.5 kg quetiapine 68.4 kg risperidone. Weight gain occurred during treatment with all three drugs. Compared with risperidone mean weight gain was higher with olanzapine (adjusted co-efficient +1.24 kg (95% confidence interval: 0.69–1.79 kg per six months) for men and +0.77 kg (95% confidence interval: 0.29–1.24 kg) for women). Weight gain with quetiapine was lower in unadjusted models compared with risperidone, but this difference was not significant after adjustment.

Conclusion:

Olanzapine is more commonly prescribed to people with lower weight. However, after accounting for baseline weight, age, sex and diagnosis, olanzapine is still associated with greater weight gain over two years than risperidone or quetiapine. Baseline weight does not ameliorate the risks of weight gain associated with antipsychotic medication. Weight gain should be assertively discussed and managed for people prescribed antipsychotics, especially olanzapine.

Keywords

Cohort study primary care second generation antipsychotics weight gain

Get full access to this article

View all access options for this article.

References

Bak

Fransen

Janssen

et al . (2014) Almost all antipsychotics result in weight gain: A meta-analysis. PLoS One 9: e94112.

Bushe

Slooff

Haddad

et al . (2012) Weight change from 3-year observational data: Findings from the worldwide schizophrenia outpatient health outcomes database. J Clin Psychiatry 3: e749–e755.

Chisholm

(1990) The read clinical classification. Br Med J 300: 1092.

Cooper

Reynolds

Barnes

TRE

et al . (2016) BAP guidelines on the management of weight gain, metabolic disturbances and cardiovascular risk associated with psychosis and antipsychotic drug treatment. J Psychopharmacol 30: 717–748.

Daskalopoulou

George

Walters

et al . (2016) Depression as a risk factor for the initial presentation of twelve cardiac, cerebrovascular, and peripheral arterial diseases: Data linkage study of 1.9 million women and men. PLoS One 11: e0153838.

Davé

Petersen

(2009) Creating medical and drug code lists to identify cases in primary care databases. Pharmacoepidemiol Drug Saf 18: 704–707.

de Hert

Dekker

Wood

et al . (2009) Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 24: 412–424.

Haddad

(2005) Weight changes with atypical antipsychotics in the treatment of schizophrenia. J Psychopharmacol 19: 16–27.

In Practice Systems Ltd. (2016) The Health Improvement Network (THIN). Available at: http://www.inps.co.uk/vision/health-improvement-network-thin (accessed 24 April 2018).

10.

Leucht

Cipriani

Spineli

et al . (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple treatments meta-analysis. Lancet 382: 951–962.

11.

Maguire

Blak

Thompson

(2009) The importance of defining periods of complete mortality reporting for research using automated data from primary care. Pharmacoepidemiol Drug Saf 18: 76–83.

12.

Manu

Dima

Shulman

et al . (2015). Weight gain and obesity in schizophrenia: Epidemiology, pathobiology, and management. Acta Psychiatr Scand 132: 97–108.

13.

Marston

Nazareth

Petersen

et al . (2014) Prescribing of antipsychotics in UK primary care: A cohort study. BMJ Open 4: e006135.

14.

Moreno

Nuevo

Chatterji

et al . (2013) Psychotic symptoms are associated with physical health problems independently of a mental disorder diagnosis: Results from the WHO World Health Survey. World Psychiatry 12: 251–257.

15.

Musil

Obermeier

Russ

et al . (2015) Weight gain and antipsychotics: A drug safety review. Expert Opin Drug Saf 14: 73–96.

16.

Osborn

Hardoon

Omar

et al . (2015) Cardiovascular risk prediction models for people with severe mental illness: Results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry 72: 143–151.

17.

Osborn

DPJ

Levy

Nazareth

et al . (2007) Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom’s General Practice Research Database. Arch Gen Psychiatry 64: 242–249.

18.

Osborn

DPJ

Wright

Levy

et al . (2008) Relative risk of diabetes, dyslipidaemia, hypertension and the metabolic syndrome in people with severe mental illnesses: Systematic review and metaanalysis. BMC Psychiatry 8: 843.